LAVAL, QC, Sept. 15 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) reported today that its distributor
Schiff Nutrition International Inc. has launched Schiff(R) MegaRed(TM)
containing Neptune Krill Oil (NKO(R)) in Walgreens, which represents the
largest retail pharmacy chain in the United States with over 6,400 drug stores
nationwide. Schiff(R) MegaRed(TM) has been made available at all locations.
Walgreens, founded in 1901, is considered the leader in innovative
drugstore retailing setting new standards in the industry with its modern
store and pharmacy features. Walgreens reported fiscal year 2007 revenues of
over $53 billion and is serving 5 million customers daily chainwide. Walgreens
reports that it expects to operate more than 7,000 stores in 2010(1).
"We continue to execute on our expansion strategy to seek strong
penetration in mass retail channels, and now with distribution in Costco and
Walgreens, the consumer mass market represents a fast growing sales segment
for Neptune driven by brand recognition and consumer acceptance. Neptune Krill
Oil's unique composition of proprietary bioactive ingredients of
functionalized phospholipid omega-3 fatty acids and powerful anti-oxidants
enables the positioning of NKO(R) as a premium product in the marketplace,"
stated Thierry Houillon, Vice-President, Nutraceutical of Neptune.
"Premium products within the worldwide marine omega-3 market such as
Neptune Krill Oil are gaining major market share driven by consumer demand for
natural health and wellness products with proven therapeutic benefits. The
high-end omega-3 market is growing at an annual rate of between 20 and
30 percent. This trend will provide the Company, as a recognized innovator and
market leader, with an opportunity to generate high sales growth of its
products which enforces the Company's strategic plan to expand productivity
and capacity by rapidly completing the in-house capacity expansion program and
by also partnering with a strategic industrial manufacturing company within
the short term for substantial additional capacity," added Mr. Thierry
NKO(R) is a proprietary phospholipid omega-3 composition extracted from
Antarctic Krill and patented for its extraction process, composition and for
its medicinal use. NKO(R)'s safety and health benefits have been demonstrated
by clinical studies in hyperlipidemia (high cholesterol), premenstrual
syndroms, inflammation and arthritic disease. The development of several
functional food product lines as well as pharmaceutical product opportunities
for three pharmaceutical markets including the over-the-counter, the
prescription medical food and prescription drug market are currently underway.
Neptune researches and develops proprietary bioactive ingredients and
products for nutraceutical and pharmaceutical applications and is carrying out
clinical research to show the therapeutic benefits in various medical
indications. The Company patents and protects its innovations and continuously
expands its intellectual property portfolio. Neptune has already obtained many
regulatory approvals allowing commercialization of its products in various
geographic markets and has filed for and is expecting additional approvals.
Neptune continues to strongly support its strategic development plan to form
partnership with worldwide leaders in the nutraceutical industries. Neptune
signed agreements with Nestlé and Yoplait, worldwide leading food
manufacturers, and paved its entrance into the global functional food market.
Neither NASDAQ nor TSX Venture Exchange accepts responsibility for the
adequacy or accuracy of this press release.
(1) Walgreens at www.walgreens.com
Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results
of the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
particular, readers are cautioned that outlooks and projections of future
results presented in this press release should be considered uncertain and
forward-looking. In addition to statements which explicitly describe such
risks and uncertainties, readers are urged to consider statements labeled with
the terms "believes," "belief," "expects," "intends," "anticipates," "will,"
or "plans" to be uncertain and forward-looking. The forward-looking statements
contained herein are also subject generally to other risks and uncertainties
that are described from time to time in the Company's reports filed with the
Securities and Exchange Commission and the Canadian securities commissions.
For further information:
For further information: Toni Rinow, Ph.D., MBA Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,
firstname.lastname@example.org; www.neptunebiotech.com; Source: Neptune
Technologies & Bioressources Inc.